Type-1 Diabetes Treatment Market Research Report - Forecast till 2027

Type-1 Diabetes Treatment Market Research Report: By Product (Rapid-Acting Insulin, Short-Acting Insulin, Medium-Acting Insulin, Long-Acting Insulin, Others) and By End User (Hospitals and Clinics, Specialty Centers, Others) – Forecast to 2027

ID: MRFR/HC/6727-HCR | February 2021 | Region: Global | 111 pages

Type-1 Diabetes Treatment Market overview


The CAGR for the type 1 diabetes market is expected to be 7.9% until the end of 2025. The market is expected to be worth USD 9.6 billion by then. Type 1 diabetes is rare. There are two types of diabetes that humans can get. Type 1 diabetes currently accounts for a tenth of all diabetes cases around the world!


People develop this type of diabetes when their bodies either don’t make any insulin or fail to make enough insulin to process all of the refined and other types of sugars that they may eat on a daily basis! Young people who are obese tend to develop type 1 diabetes the most. What worsens matters in terms of type 1 diabetes is that the young will age rapidly. They tend to adopt unhealthy lifestyles as they age. This encourages type 1 diabetes to stay with them.


COVID-19 analysis of Type 1 Diabetes Market 


COVID-19 proved to be a dangerous virus last year. There was no vaccine for it until early this year. Governments sought to contain the virus by imposing temporary quarantines and indefinite lockdowns. This had disastrous consequences for those who did not test positive for COVID-19.


People with other conditions like diabetes, cancer, etc. were not able to get the treatment when they needed it simply because many doctors and other health providers were refusing to see people who didn’t have deadly health problems. This delay is what caused many people with Type 1 diabetes to get deathly ill or even die!


Market dynamics


Drivers


The increased adoption of Western diet and lifestyles which encourage eating a high-fat diet and engaging in little to no exercise are two of the major drivers behind type 1 diabetes. More and more people around the world have access to insurance. This helps them afford the otherwise prohibitively expensive diabetes medicines. This is a major contributor to growth in the type 1 diabetes market.


More people are aware of type 1 diabetes and the short and long-term damage that it can do to the body. This is also a major factor that’s driving growth in the type 1 diabetes market!


Opportunities


The fact that the type 1 diabetes market is growing rapidly and the fact that this market is very lucrative has encouraged many companies that make medicines to manage this dangerous ‘sweet disease’ to invest heavily in research and development. This has allowed them to develop and type 1 diabetes market a new generation of powerful medicines that are much more expensive and much more effective in terms of treating type 1 diabetes. One of these medicines is Januvia.


Restraints


There are some factors that are holding growth back in the type 1 diabetes market. These are the fact that most nations around the world have very strict guidelines in terms of approving newer and more powerful diabetes medications. Another very important factor is the fact that all of these medicines, while powerful and helpful in managing type 1 diabetes, can have annoying and sometimes even potentially dangerous side effects.


Challenges


A key challenge that companies that produce insulin and related medicines will face in the short and long-term future lies in making sure that the newer generations of medicines are safer and more effective than the previous generations. These companies also have to ensure that these medicines remain affordable for the global masses.


Cumulative growth analysis


The CAGR for the type 1 diabetes market is 7.9%. The market is expected to be worth USD 9.6 billion by then.


Technology analysis


Eli Lilly is a major American player in the type 1 diabetes market. It has managed to retain its superior position by investing heavily in research and development. One example of a new generation medicine for diabetes management is Trulicity. This powerful medicine can lower blood sugar levels and blood pressure after the first use. Diabetics commonly suffer from higher blood pressure.


Type 1 Diabetes Market Segment overview


By type


There are two main types of diabetes:  type 1 diabetes and type 2 diabetes.


By Product


There are many medicines on the type 1 diabetes market to help people with either type 1 or type 2 diabetes manage their condition better. Some of these are:



  • Lantus

  • Januvia

  • Humalog

  • Novorapid

  • Humalin

  • Galvus


By End User



  • Hospitals & Clinics

  • Specialty Centers


Regional analysis


Diabetes is becoming more of a problem as the world develops and grows richer. The North American region has the largest type 1 diabetes market share. For example, the United States alone spends at least 11% of its national budget on diabetes treatment and research.


Changing lifestyles in the Asia-Pacific region means that it will have the highest regional CAGR. there are two nations in particular that deserve particular mention. These are India and China! There are already 120 million diagnosed cases. It’s important to remember that many more people suffer from type 1 diabetes in these two countries. It’s just that diagnosis and documentation methods are so poor in these two nations.


Companies and various governments are stepping in to help treat diabetics in the Asia-Pacific region who otherwise would not be able to afford or have access to various medicines.


The European Union has the second-largest type 1 diabetes market share. This is largely driven by the fact that more and more Europeans are gravitating away from their traditionally healthy diet and lifestyles and are adopting American diets and lifestyles which are considered to be less healthy.


Type 1 Diabetes Market Competitive landscape


The type 1 diabetes market remains very competitive. The fact that there are many large players in the industry is a major contributing factor. However, the fact that new companies are constantly entering the market is another key contributing factor. These companies are motivated to enter because of the huge and growing market share and the huge revenue generation opportunities that this market presents.


Companies are investing heavily in research and development. This allows them to develop and market (after approval from various food and drug regulatory agencies around the world) these medicines. These medicines are more powerful and this is part of what allows these companies to justify charging very high prices for them (the medicines.)


However, this can only go so far. This is especially true because most companies are developing and marketing similar medicines and insulin delivery devices. Companies are finding that they must, therefore, become creative. They are doing so by entering into joint ventures (also known as strategic partnerships.)


The resulting companies have access to more money and other resources when they enter into strategic partnerships. This allows them to invest even more in research and development. They have the opportunity to develop newer and more powerful medicines that are more expensive before the competitors even learn about them (the medicines.) This gives the companies in the strategic partnership a sustainable competitive advantage.


These companies are also in a good position to enter into new markets and possibly even displace entrenched companies with newer medicines that are more powerful and effective. Companies in a strategic partnership can even guarantee entry into strategic new markets by slightly lowering the prices at which they sell their medicines. Of course, they can also solidify their positions in existing markets.


Companies have found that they can merge with/acquire other companies in similar fields that do similar things in terms of developing and marketing medicines and insulin delivery systems. This gives them a strategic and sustainable competitive advantage because it allows them to have access to more money and other resources. They are in a much better position to develop a new generation of blockbuster medicines which they can then type 1 diabetes market.


Once they have done this, they can enter into new markets quickly and easily. They may even be able to displace existing companies with their newer and better medicines and related products. Of course, they can always and also solidify their existing positions in current markets.


Eli Lilly is a major American contender in the type 1 diabetes market. It has managed to survive largely because it invested heavily in research and development. It now sells powerful medicines like Humalog and Humulin.


List of companies



  • Astellas Pharma (Japan)

  • Eli Lilly (US)

  • Merck (US)

  • Novo Nordisk (Denmark)

  • Sanofi (France)

  • AstraZeneca (UK)

  • Boehringer Ingelheim GmbH (Germany)

  • Novartis (Switzerland)

  • Pfizer Inc. (US)

  • Abbott Laboratories (US)

  • Mannkind Corporation (US)

  • Braun Melsungen AG (Germany)

  • Macrogenics, Inc. (US)

  • DiaVacs, Inc. (US)

  • Biodel, Inc. (US)


Recent developments



  • Eli Lilly proves that Jardiance can successfully save lives and keep people out of heart failure for longer.


Report overview


The type 1 diabetes market is growing at a CAGR of 7.9% until the end of 2025. The type 1 diabetes market is expected to be worth USD 9.6 billion by then. Increasing adoption of Western lifestyles is driving growth as is the fact that more governments are educating people about type 1 diabetes. There is also more awareness about this ‘sweet disease.’ Also, more and more people around the world are able to afford these medicines because they have access to insurance.



Report Scope:
Report Attribute/Metric Details
  Market Size   2025:Significant Value
  CAGR   2018-2023: 7.9%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Astellas Pharma (Japan), Eli Lilly (US), Merck (US), Novo Nordisk (Denmark), Sanofi (France), AstraZeneca (UK), Boehringer Ingelheim GmbH (Germany), Novartis (Switzerland), Pfizer Inc. (US), Abbott Laboratories (US), Mannkind Corporation (US), Braun Melsungen AG (Germany), Macrogenics, Inc. (US), DiaVacs, Inc. (US), Biodel, Inc. (US)
  Key Market Opportunities   Research and Development
  Key Market Drivers

  • Rising prevalence of type-1 diabetes due to environmental and genetic factors
  • Growing geriatric population, which is susceptible to type-1 diabetes
  • Increasing prevalence of obesity, which is a contributing factor
  • Rising worldwide spending on healthcare
  • Growing access to medication worldwide


  • Frequently Asked Questions (FAQ) :


    The type-1 diabetes treatment market is projected to grow at a 7.9% CAGR between 2019-2025.

    The Americas are predicted to dominate the type-1 diabetes treatment market.

    The type-1 diabetes treatment market is predicted to touch USD 9.6 billion by 2025.

    Increasing prevalence of type-1 diabetes, rising incidence of obesity, and government support are boosting market growth.

    Strict approval process and side effects may restrict market growth.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.